This article is more than 5 years old. Information may no longer be current.
FDA warns against use of PNC-27 for cancer treatment
The FDA today issued a warning urging consumers not to buy or use PNC-27 as a treatment for cancer.
An FDA laboratory discovered Variovorax paradoxus bacteria in a PNC-27 solution sample for inhalation, according to an agency-issued press release.
Individuals who use a contaminated product could develop serious, potentially life-threatening infections, according to FDA. Young children, the elderly, pregnant women and those with weakened immune systems would be at the greatest risk.
The product is available through a website that promotes PNC-27 as “an important protein in the fight against cancer.”
The FDA has not evaluated the safety or efficacy of PNC-27, nor has the agency improved the product for treatment of any disease, including cancer.
PNC-27 may be available in a variety of forms, according to the FDA. These include nebulized solution, IV solution, rectal suppository and vaginal suppository.
The FDA has not received reports of any serious adverse events or illnesses related to PNC-27. However, the agency urged anyone who has used PNC-27 and has concerns to contact their health care provider.